Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182. Article

Full Text via DOI: 10.1200/JCO.2019.37.15_suppl.4504 Web of Science: 000487345805331

Cited authors

  • Galsky, Matt D.; Pal, Sumanta K.; Mortazavi, Amir; Milowsky, Matthew I.; George, Saby; Gupta, Sumati; Fleming, Mark T.; Dang, Long H.; Geynisman, Daniel M.; Walling, Radhika; Alter, Robert S.; Robin, Erwin L.; Wang, Jue; Gupta, Shilpa; Chism, David D.; Picus, Joel; Philips, George; Quinn, David I.; Hahn, Noah M.; Yu, Menggang

Publication date

  • 2019

Published in

International Standard Serial Number (ISSN)

  • 0732-183X


  • 37


  • 15